<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7263255\results\search\testTrace\results.xml">
  <result pre="advancements and future perspective of ongoing research for therapy and" exact="detection" post="of SARS-CoV-2 are provided. The review, in brief, summarizes"/>
  <result pre="are Î²-CoVs. In the 21st century, two severe respiratory tract" exact="infection" post="(RTI) viz. severe acute respiratory syndrome (SARS) caused by"/>
  <result pre="Assessment of the patients for viral pneumonia was done by" exact="testing" post="the broncho-alveolar lavage fluid using polymerase chain reaction, whole-genome"/>
  <result pre="pneumonia was done by testing the broncho-alveolar lavage fluid using" exact="polymerase chain reaction," post="whole-genome sequencing and cell culturing. Chinese government notified the"/>
  <result pre="between humans. All the domestic and international airports had a" exact="screening" post="mechanism in place in order to detect any symptomatic"/>
  <result pre="order to detect any symptomatic travelers who were kept under" exact="quarantine" post="and were allowed to go if they tested negative"/>
  <result pre="remdesivir, which has entered into clinical trials now for the" exact="treatment" post="of COVID-19, also inhibits the activity of RdRp. 4"/>
  <result pre="RdRp. 4 Enzymes and pathways as potential therapeutic targets Upon" exact="infection" post="from any microbes, the proteins exposed on the surface"/>
  <result pre="with synthetic drugs would not only help in combating the" exact="infection" post="but might also enable in the recovery of defence"/>
  <result pre="be addressed by the therapeutics development. Drugs to combat SARS-CoV-2" exact="infection" post="are in search. In particular, proteins of SARS-CoV-2 such"/>
  <result pre="as its pathogenesis and proliferation pathways still remain unknown. The" exact="treatment" post="is based on symptoms, and oxygen therapy is the"/>
  <result pre="is based on symptoms, and oxygen therapy is the main" exact="treatment" post="method for severely infected patients. In cases of respiratory"/>
  <result pre="assistance is important for septic shock management [56]. However, therapeutic" exact="treatment" post="is a must for the future and some of"/>
  <result pre="and some of available drugs can be repurposed for the" exact="treatment" post="of COVID-19. There are many choices for containing or"/>
  <result pre="investigational drugs for new uses that are authorized for the" exact="treatment" post="of other diseases [58]. About one-third of the approvals"/>
  <result pre="broad-spectrum antiviral drug [62,63]. CQ is reported to prevent virus" exact="infection" post="by elevating the endosomal pH needed for virus/cell fusion"/>
  <result pre="far shown that chloroquine phosphate is preferred in managing the" exact="treatment" post="by constraining the worsening of pneumonia, increasing lung imaging"/>
  <result pre="activity to that of CQ, may function as a safer" exact="treatment" post="method for COVID 19, as it demonstrates anti-SARS-CoV activity"/>
  <result pre="chart defined protocol, and 6 patients obtained simultaneous azithromycin (AZM)" exact="treatment" post="to avoid bacterial superinfection. Patients who received AZM were"/>
  <result pre="protease inhibitors like LPV and RTV in patients with COVID-19" exact="infection" post="[66]. Initially, LPV and RTV were suspected to suppress"/>
  <result pre="HIV protease inhibitors modify host pathways to interact with coronavirus" exact="infection" post="indirectly, their potency remains a matter of concern. In"/>
  <result pre="developed by Gilad Sciences. Inc in 2015 primarily for the" exact="treatment" post="of Ebola and it is in Phase -II trials"/>
  <result pre="load in primary human epithelial cell cultures. RDV blocks SARS-CoV" exact="infection" post="at a micromolecular and at a half cytotoxic concentration"/>
  <result pre="is the main reason for considering RBV as a potential" exact="treatment" post="approach to treat SARS-CoV-2 [89]. High doses of RBV"/>
  <result pre="both RBV and interferon-Î±, thus making RBV as a promising" exact="treatment" post="for COVID-19 [90]. The pharmacokinetic profile of RBV is"/>
  <result pre="The half-life of RBV is about 120â€&quot;170Â h. For the" exact="treatment" post="of COVID-19, intravenous RBV is given in a dose"/>
  <result pre="time, recovery and reduce the mortality in patients with COVID-19" exact="infection" post="compared with lopinavir/ ritonavir [94]. 5.1.2.4 Arbidol Arbidol (ARB)"/>
  <result pre="drug currently approved in China and Russia for the prophylaxis" exact="treatment" post="of respiratory viral infections and influenza [95]. It is"/>
  <result pre="of researchers in the use of ARB as a potential" exact="treatment" post="therapy alone or in combination therapy to treat COVID-19."/>
  <result pre="COVID-19 and has recommended the use of ARB as a" exact="treatment" post="option. A study conducted in China reveals that ARB"/>
  <result pre="study conducted in China reveals that ARB effectively inhibits SARS-CoV-2" exact="infection" post="at low concentration of 10â€&quot;30Â Î¼M in vitro. The"/>
  <result pre="Diagnosis and Treatment of Novel Coronavirus-induced Pneumonia for the tentative" exact="treatment" post="of COVID-19. ARB is rapidly absorbed following its oral"/>
  <result pre="to observe the safety and efficacy of ARB in the" exact="treatment" post="of pneumonia induced by SARS-CoV-2 [105]. Another randomized, open"/>
  <result pre="combination with ARB and recombinant human interferon-Î± 2b in the" exact="treatment" post="of mild to moderate COVID-19 pneumonia has also been"/>
  <result pre="clinical effectiveness of FPV in influenza in low-dose and high-dose" exact="treatment" post="modalities with no mortality and no substantial possibility of"/>
  <result pre="effect [109]. Evidently, FPV in Influenza could contribute to positive" exact="treatment" post="interventions. FPV may also have possible antiviral activity on"/>
  <result pre="an RNA virus. A clinical study on FPV for the" exact="treatment" post="of COVID-19 conducted by the Shenzhen Third People's Hospital"/>
  <result pre="/ RTV. There were no major adverse reactions in the" exact="treatment" post="group FPV, and there were slightly less adverse effects"/>
  <result pre="The other antiviral drugs are also widely used in COVID-19" exact="treatment" post="around the world. Oseltamivir is another medication licensed for"/>
  <result pre="around the world. Oseltamivir is another medication licensed for the" exact="treatment" post="of influenza A and B; it prevents the viral"/>
  <result pre="cells [118]. These are the body's natural defense against viral" exact="infection" post="and also play an important role in combating tumors"/>
  <result pre="tumors and regulating immunity. FDA has approved INFs for the" exact="treatment" post="of various conditions like multiple sclerosis, hepatitis B and"/>
  <result pre="of SARS-CoV [123] and MERS-CoV [124]. With respect to coronavirus" exact="infection" post="INFÎ²1 plays an important role because of its protective"/>
  <result pre="studies showed that INF can be used in the prophylactic" exact="treatment" post="of COVID-19. INF is an investigational drug and hence"/>
  <result pre="efficacy of recombinant INFÎ±1b as monotherapy in treating corona virus" exact="infection" post="[126]. In another case, an randomized open-label controlled trial"/>
  <result pre="INFÎ²1b in comparison with monotherapy of lopinavir/ ritonavir as a" exact="treatment" post="for novel coronavirus infection has been planned [94]. Peginterferon"/>
  <result pre="monotherapy of lopinavir/ ritonavir as a treatment for novel coronavirus" exact="infection" post="has been planned [94]. Peginterferon alfa-2a marketed as Pegasys"/>
  <result pre="(NCT04343976) and Pegylated INF Lamda-1A (NCT04388709) in patients with COVID-19" exact="infection" post="have been initiated [127,128]. 5.1.3 Antibiotic 5.1.3.1 Azithromycin Azithromycin"/>
  <result pre="synthetic broad spectrum macrolide antibiotic approved by FDA for the" exact="treatment" post="of genitourinary tract infections, enteric and respiratory tract related"/>
  <result pre="AZ is effective in reducing the viral load in the" exact="treatment" post="of COVID-19. Usually a dose of 1â€&quot;2Â g of"/>
  <result pre="in combination with hydroxychloroquine or chloroquine is used in the" exact="treatment" post="of COVID-19. There are around 81 clinical trial registered"/>
  <result pre="of COVID-19. There are around 81 clinical trial registered for" exact="testing" post="the efficacy of AZ in combination with several other"/>
  <result pre="and AZ to see which one is better in the" exact="treatment" post="of confirmed or suspected cases of COVID-19 [134]. A"/>
  <result pre="tocilizumab given in combination with azithromycin and hydroxychloroquine in the" exact="treatment" post="of SARS-CoV-2 [135]. A phase II B, double blind,"/>
  <result pre="regulation of NFKB pathways [140] and thereby aiding in the" exact="treatment" post="of COVID-19 as corona virus causes an elevated release"/>
  <result pre="improving the clinical outcomes among the patients hospitalized for the" exact="treatment" post="of COVD-19 pneumonia [151]. A placebo controlled, two-arm, double"/>
  <result pre="Baricitinib is an immunosuppressant approved by the FDA for the" exact="treatment" post="of moderate to severe rheumatoid arthritis. It is a"/>
  <result pre="in reducing the inflammation and it also prevents the viral" exact="infection" post="and endocytosis by inducing a inhibitory effect o AAK1"/>
  <result pre="the exact role and the efficacy of baricitinib in the" exact="treatment" post="of COVID-19. A phase-II, non-randomized, open labelled clinical trial"/>
  <result pre="combination therapy of lopinavir/ritonavir, hydroxychloroquine sulphate and baricitinib in the" exact="treatment" post="of moderate to severe COVD-19 in hospitalized patients [155]."/>
  <result pre="the fungus Beaueria nivea. It is widely approved for the" exact="treatment" post="of lupus nephritis vasculitis psoriatic arthritis and as a"/>
  <result pre="in decreasing the viral load [160]. Cytokine storm in SARS-CoV-2" exact="infection" post="is mainly caused due to SHL and cyclosporine is"/>
  <result pre="against SARS-CoV-2 virus it is not yet recommended for the" exact="treatment" post="of COVID-19 as there is no proper pre-clinical and"/>
  <result pre="data proving the safety and efficacy of cyclosporine in the" exact="treatment" post="of COVID-19 available. 5.1.5 Monoclonal antibodies (MAb) 5.1.5.1 Tocilizumab"/>
  <result pre="been initiated to investigate the use of TCZ in the" exact="treatment" post="of COVD-19. A multicentred, open-labelled, phase-II, single arm clinical"/>
  <result pre="is a broad-spectrum anti-parasite drug which is approved for the" exact="treatment" post="of onchocerciasis and intestinal strongyloidiasis. Ivermectin acts by selectively"/>
  <result pre="of the combination therapy of hydroxychloroquine and ivermectin I the" exact="treatment" post="of hospitalized COVD-19 patients [171]. 5.1.7 Angiotensin converting enzyme"/>
  <result pre="shock. Corticosteroids can cause damage via immunosuppressant activity during the" exact="infection" post="treatment and have failed to offer an advantage in"/>
  <result pre="Corticosteroids can cause damage via immunosuppressant activity during the infection" exact="treatment" post="and have failed to offer an advantage in many"/>
  <result pre="examining 416 COVID-19 patients, Shang et al. observed that corticosteroid" exact="treatment" post="and the administration of gamma globulin raised fatalities and"/>
  <result pre="patients, aged 34â€&quot;78Â years. The pilot study findings indicate CP" exact="treatment" post="could be a safe and effective therapeutic alternative for"/>
  <result pre="cases. Hitherto, the patients suffering from COVID-19, are receiving symptomatic" exact="treatment" post="due to the unavailability of a specific therapy. In"/>
  <result pre="the unavailability of a specific therapy. In severe cases, the" exact="treatment" post="includes support to the functioning of the vital organs"/>
  <result pre="NCT04333225, NCT04335084, NCT04323631 3 Remdesivir 3 I.V infusion Antiviral in" exact="treatment" post="of COVID-19 Gilead Sciences, NCT04292899, NCT04292730 4 Azithromycin 3"/>
  <result pre="NCT04336904 24 Huaier Granule 2 &amp;amp; 3 Oral route Adjuvant" exact="treatment" post="of COVID-19 Tongji Hospital, China NCT04291053 25 Tranexamic acid"/>
  <result pre="3 Oral route Antipsychotics, to repurpose the drug for COVID-19" exact="treatment" post="Centre Hospitalier St Anne, France NCT04366739 33 Lenalidomide 4"/>
  <result pre="1 â€&quot; To identify the maximum tolerated dose for the" exact="treatment" post="of COVID-19 Masonic Cancer Center, University of Minnesota NCT04363346"/>
  <result pre="there are no officially approved drugs and vaccines for the" exact="treatment" post="of COVID-19. Hence, we must rely solely on implementing"/>
  <result pre="authors reported that HZQ-AZ combination is a safe and effective" exact="treatment" post="if begun immediately after diagnosis, and in most cases"/>
  <result pre="replication, transmission and pathogenesis also integrating the imaging and molecular" exact="diagnosis" post="will help to efficiently track and treat COVID-19 [19,198,199]."/>
  <result pre="has proved to be the most efficient approach towards the" exact="treatment" post="of COVID-19. Drugs from various therapeutic category alone or"/>
  <result pre="with the severity as well as with subjects on which" exact="treatment" post="is being done. In case of vaccines, multiple vaccines"/>
  <result pre="membrane fusionCellular &amp;amp; Molecular Immunology20201310.1038/s41423-020-0424-931611651 47XiaS.LiuM.WangC.XuW.LanQ.FengS.QiF.BaoL.DuL.LiuS.QinC.SunF.ShiZ.ZhuY.JiangS.LuL.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
  <result pre="strategy in COVID-19Int. J. Biol. Sci.1620201724173110.7150/ijbs.4549832226290 56CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features, evaluation and" exact="treatment" post="coronavirus (COVID-19)StatPearls2020StatPearls PublishingTreasure Island (FL)http://www.ncbi.nlm.nih.gov/books/NBK554776/ 57LiG.ClercqE.D.Therapeutic options for the"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res.23201330030210.1038/cr.2012.16523208422 64VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent"/>
  <result pre="modelCell Res.23201330030210.1038/cr.2012.16523208422 64VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 65WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and chloroquine effectively inhibit the"/>
  <result pre="8, 2020). 67GaoJ.TianZ.YangX.Breakthrough: Chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci Trends142020727310.5582/bst.2020.0104732074550 68BiotC.DaherW.ChavainN.FandeurT.KhalifeJ.DiveD.De"/>
  <result pre="antiviral activitiesJ. Med. Chem.4920062845284910.1021/jm060185616640347 69MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.American academy of ophthalmology, recommendations on" exact="screening" post="for chloroquine and hydroxychloroquine retinopathy (2016 revision)Ophthalmology.12320161386139410.1016/j.ophtha.2016.01.05826992838 70D. Zhou,"/>
  <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progression, J. Antimicrob. Chemother.. (n.d.). doi:10.1093/jac/dkaa114. 71GautretP.LagierJ.C.ParolaP.HoangV.T.MeddedL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoreS.ColsonP.ChabriereE.ScolaB.L.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and"/>
  <result pre="disease 2019 in Korea: the application of lopinavir/ritonavir for the" exact="treatment" post="of COVID-19 pneumonia monitored by quantitative RT-PCRJ. Korean Med."/>
  <result pre="virus challengeSci. Transl. Med.112019eaau924210.1126/scitranslmed.aau924231142680 77BarlowA.LandolfK.M.BarlowB.YeungS.Y.A.HeavnerJ.J.ClaassenC.W.HeavnerM.S.Review of emerging pharmacotherapy for the" exact="treatment" post="of coronavirus disease 2019Pharmacotherapy202010.1002/phar.2398 78SheahanT.P.SimsA.C.LeistS.R.SchÃ¤ferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.SpahnJ.E.BauerL.SellersS.PorterD.FengJ.Y.CihlarT.JordanR.DenisonM.R.BaricR.S.Comparative therapeutic efficacy of remdesivir"/>
  <result pre="of the pharmacokinetic and pharmacodynamic properties of drugs considered for" exact="testing" post="in human efficacy trialsClin. Pharmacokinet.55201690792310.1007/s40262-015-0364-126798032 82Severe 2019-nCoV Remdesivir RCT"/>
  <result pre="- ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04292899 (accessed April 9, 2020). 85Adaptive COVID-19" exact="treatment" post="trial (ACTT) - full text view - ClinicalTrials.gov, (n.d.)."/>
  <result pre="(n.d.). Https://Clinicaltrials.Gov/Ct2/Show/Nct04280705 (accessed April 9, 2020). 86TanE.L.C.OoiE.E.LinC.-Y.TanH.C.LingA.E.LimB.StantonL.W.Inhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugsEmerg. Infect. Dis.10200458158610.3201/eid1004.03045815200845"/>
  <result pre="drugsEmerg. Infect. Dis.10200458158610.3201/eid1004.03045815200845 87TeH.S.RandallG.JensenD.M.Mechanism of action of ribavirin in the" exact="treatment" post="of chronic hepatitis CGastroenterol Hepatol (N Y)3200721822521960835 88GraciJ.D.CameronC.E.Mechanisms of"/>
  <result pre="syndrome in CanadaClin. Infect. Dis.3720031139114210.1086/37830414523782 93ChuC.M.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.H.ChanK.S.KaoR.Y.T.PoonL.L.M.WongC.L.P.GuanY.PeirisJ.S.M.YuenK.Y.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax59200425225610.1136/thorax.2003.01265814985565 94Lopinavir/Ritonavir, Ribavirin"/>
  <result pre="and clinical findingsThorax59200425225610.1136/thorax.2003.01265814985565 94Lopinavir/Ritonavir, Ribavirin and IFN-beta combination for nCoV" exact="treatment" post="- full text view - ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04276688 (accessed"/>
  <result pre="Medical and Health Care (CPAM)A rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
  <result pre="Health Care (CPAM)A rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)Military"/>
  <result pre="Medical Research72020410.1186/s40779-020-0233-632029004 105Clinical study of arbidol hydrochloride tablets in the" exact="treatment" post="of pneumonia caused by novel coronavirus - full text"/>
  <result pre="and safety of bromhexine hydrochloride tablets combined with standard treatment/standard" exact="treatment" post="in patients with suspected and mild novel coronavirus pneumonia"/>
  <result pre="evidenceTravel Med. Infect. Dis.202010171010.1016/j.tmaid.2020.10171032360327 108Dose-finding study of favipiravir in the" exact="treatment" post="of uncomplicated influenza, ClinicalTrials.Gov. (n.d.). https://clinicaltrials.gov/ct2/show/NCT01068912 (accessed May 16,"/>
  <result pre="2020). 109Phase 3 efficacy and safety study of favipiravir for" exact="treatment" post="of uncomplicated influenza in adults - T705US316, ClinicalTrials.Gov. (n.d.)."/>
  <result pre="- T705US316, ClinicalTrials.Gov. (n.d.). https://clinicaltrials.gov/ct2/show/NCT02026349 (accessed May 16, 2020). 110CaiQ.YangM.LiuD.ChenJ.ShuD.XiaJ.LiaoX.GuY.CaiQ.YangY.ShenC.LiX.PengL.HuangD.ZhangJ.ZhangS.WangF.LiuJ.ChenL.ChenS.WangZ.ZhangZ.CaoR.ZhongW.LiuY.LiuL.Experimental" exact="treatment" post="with favipiravir for COVID-19: an open-label control studyEngineering202010.1016/j.eng.2020.03.007 111Researchers"/>
  <result pre="17, 2020). 112LuH.Efficacy and safety of darunavir and cobicistat for" exact="treatment" post="of COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT042522742020 113SantosJ.R.CurranA.Navarro-MercadeJ.AmpueroM.F.PelaezP.PÃ©rez-AlvarezN.ClotetB.ParedesR.MoltÃ³J.Simplification of antiretroviral treatment from darunavir/ritonavir"/>
  <result pre="and cobicistat for treatment of COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT042522742020 113SantosJ.R.CurranA.Navarro-MercadeJ.AmpueroM.F.PelaezP.PÃ©rez-AlvarezN.ClotetB.ParedesR.MoltÃ³J.Simplification of antiretroviral" exact="treatment" post="from darunavir/ritonavir monotherapy to darunavir/cobicistat monotherapy: effectiveness and safety"/>
  <result pre="novel pharmacokinetic enhancer without anti-HIV activityClinical Pharmacology &amp;amp; Therapeutics87201032232910.1038/clpt.2009.22820043009 115UyekiT.M.Oseltamivir" exact="treatment" post="of influenza in childrenClin. Infect. Dis.6620181501150310.1093/cid/cix115029315362 116WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.WangB.XiangH.ChengZ.XiongY.ZhaoY.LiY.WangX.PengZ.Clinical characteristics of"/>
  <result pre="the emerging Middle East respiratory syndrome coronavirusJ. Infect.67201360661610.1016/j.jinf.2013.09.02924096239 125ShenK.-L.YangY.-H.Diagnosis and" exact="treatment" post="of 2019 novel coronavirus infection in children: a pressing"/>
  <result pre="syndrome coronavirusJ. Infect.67201360661610.1016/j.jinf.2013.09.02924096239 125ShenK.-L.YangY.-H.Diagnosis and treatment of 2019 novel coronavirus" exact="infection" post="in children: a pressing issueWorld J. Pediatr.202010.1007/s12519-020-00344-6s12519-020-00344â€&quot;6 126Efficacy and"/>
  <result pre="issueWorld J. Pediatr.202010.1007/s12519-020-00344-6s12519-020-00344â€&quot;6 126Efficacy and safety of IFN-Î±2Î² in the" exact="treatment" post="of novel coronavirus patients - full text view -"/>
  <result pre="ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04293887 (accessed April 10, 2020). 127Pegylated interferon lambda" exact="treatment" post="for COVID-19 - full text view - ClinicalTrials.gov, (n.d.)."/>
  <result pre="in J774 macrophagesExp. Cell Res.28120028610010.1006/excr.2002.561312441132 132LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.WangM.AliyariS.R.LiX.-F.WuA.MaF.ShiY.Nielsen-SainesK.JungJ.U.QinF.X.-F.QinC.-F.ChengG.Azithromycin protects against zika virus" exact="infection" post="by upregulating virus-induced Type I and III interferon responsesAntimicrob."/>
  <result pre="of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the" exact="treatment" post="of COVID-19 - full text view - ClinicalTrials.gov, (n.d.)."/>
  <result pre="(accessed May 18, 2020). 137GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt."/>
  <result pre="and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus" exact="infection" post="as identified by temporal kinome analysisAntimicrob. Agents Chemother.5920151088109910.1128/AAC.03659-1425487801 151GuptaN.Sirolimus"/>
  <result pre="infection as identified by temporal kinome analysisAntimicrob. Agents Chemother.5920151088109910.1128/AAC.03659-1425487801 151GuptaN.Sirolimus" exact="treatment" post="in hospitalized patients with COVID-19 pneumonia (The SCOPE Trial),"/>
  <result pre="2020). 156Clinical trial to evaluate efficacy of 3 types of" exact="treatment" post="in patients with pneumonia by COVID-19 - full text"/>
  <result pre="BREVACTA: pharmacokinetic and pharmacodynamic analysis of subcutaneousJ. Clin. Pharmacol.57201745946810.1002/jcph.82627599663 163XuX.HanM.LiT.SunW.WangD.FuB.ZhouY.ZhengX.YangY.LiX.ZhangX.PanA.WeiH.Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc. Natl. Acad. Sci."/>
  <result pre="study on the efficacy and tolerability of tocilizumab in the" exact="treatment" post="of patients with COVID-19 pneumonia, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043170922020 167The use of"/>
  <result pre="the SARS-CoV-2 spike glycoproteinCell1812020281292.e610.1016/j.cell.2020.02.05832155444 175Clinical management of severe acute respiratory" exact="infection" post="when COVID-19 is suspected, (n.d.). https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed April 10,"/>
  <result pre="(accessed April 10, 2020). 176RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet395202047347510.1016/S0140-6736(20)30317-232043983 177AlhazzaniW.MÃ¸llerM.H.ArabiY.M.LoebM.GongM.N.FanE.OczkowskiS.LevyM.M.DerdeL.DzierbaA.DuB.AboodiM.WunschH.CecconiM.KohY.ChertowD.S.MaitlandK.AlshamsiF.Belley-CoteE.GrecoM.LaundyM.MorganJ.S.KeseciogluJ.McGeerA.MermelL.MammenM.J.AlexanderP.E.ArringtonA.CentofantiJ.E.CiterioG.BawB.MemishZ.A.HammondN.HaydenF.G.EvansL.RhodesA.Surviving Sepsis Campaign: guidelines on"/>
  <result pre="Rev.202010255410.1016/j.autrev.2020.102554 185BlochE.M.ShohamS.CasadevallA.SachaisB.S.ShazB.WintersJ.L.van BuskirkC.GrossmanB.J.JoynerM.HendersonJ.P.PekoszA.LauB.WesolowskiA.KatzL.ShanH.AuwaerterP.G.ThomasD.SullivanD.J.PanethN.GehrieE.SpitalnikS.HodE.PollackL.NicholsonW.T.PirofskiL.BaileyJ.A.TobianA.A.R.Deployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19J. Clin. Invest.202010.1172/JCI138745 186LutzH.U.SpÃ¤thP.J.Anti-inflammatory effect of intravenous immunoglobulin"/>
  <result pre="four most promising coronavirus treatmentsScience222020 192SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and hydroxychloroquine in the" exact="treatment" post="of COVID-19 with or without diabetes: a systematic search"/>
 </snippets>
</snippetsTree>
